Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from BCAL Diagnostics Limited ( (AU:BDX) ).
BCAL Diagnostics Limited has received approximately $2.5 million from the Australian Government’s R&D Tax Incentive, aiding its development of early cancer detection tests. This funding supports the commercial launch and enhancement of its BREASTEST plus™ product, which now covers 50% of eligible women with dense breasts, bolstering BCAL’s position in the women’s health sector.
More about BCAL Diagnostics Limited
BCAL Diagnostics Limited is an Australian healthcare company focused on early cancer detection. It has launched BREASTEST plus™, a non-invasive blood test designed to improve breast disease screening and diagnostics for women with dense breasts. BCAL holds exclusive licenses for precision diagnostic tests from ClearNote Health Inc. and is listed on the Australian Securities Exchange.
Average Trading Volume: 474,638
Technical Sentiment Signal: Buy
Current Market Cap: A$33.84M
For an in-depth examination of BDX stock, go to TipRanks’ Overview page.